These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 32847479)

  • 1. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
    Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
    J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm.
    Piccini M; Loscocco GG; Gianfaldoni G; Grieco P; Palmieri G; Pilerci S; Scappini B; Bosi A
    Ann Hematol; 2020 Apr; 99(4):907-909. PubMed ID: 32030448
    [No Abstract]   [Full Text] [Related]  

  • 3. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
    Lee SS; McCue D; Pemmaraju N
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.
    Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C
    Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
    Egger A; Coello D; Kirsner RS; Brehm JE
    J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Wang SY; Thomassen K; Kurch L; Opitz S; Franke GN; Bach E; Platzbecker U; Kayser S
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e579-e582. PubMed ID: 33795208
    [No Abstract]   [Full Text] [Related]  

  • 7. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; McCue D; Lane AA; Pemmaraju N
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):941-946. PubMed ID: 31465247
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Alfayez M; Konopleva M; Pemmaraju N
    Expert Opin Biol Ther; 2020 Feb; 20(2):115-123. PubMed ID: 31801379
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
    Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Morin A; Kechedjian F; Walton P; Tavakoli A
    Clin J Oncol Nurs; 2021 Apr; 25(2):E10-E16. PubMed ID: 33739343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature.
    Beziat G; Ysebaert L; Gaudin C; Steinmeyer Z; Balardy L
    Leuk Res; 2019 Oct; 85():106199. PubMed ID: 31415942
    [No Abstract]   [Full Text] [Related]  

  • 12. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
    Hu X; Ediriwickrema A; Saleem A; Tan B; Pemmaraju N; Mannis GN
    Leuk Res; 2024 Apr; 139():107479. PubMed ID: 38492495
    [No Abstract]   [Full Text] [Related]  

  • 13. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
    Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
    Tandon A; Zhang Y; Sokol L
    Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
    Luskin MR; Lane AA
    Haematologica; 2024 Jan; 109(1):44-52. PubMed ID: 36951152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tagraxofusp in myeloid malignancies.
    Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
    Hematol Oncol; 2024 Jan; 42(1):e3234. PubMed ID: 37846131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
    Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
    Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective.
    Mirgh S; Sharma A; Folbs B; Khushoo V; Kapoor J; Tejwani N; Ahmed R; Agrawal N; Choudhary PS; Mehta P; Bhurani D
    Leuk Lymphoma; 2021 Dec; 62(12):3039-3042. PubMed ID: 34151693
    [No Abstract]   [Full Text] [Related]  

  • 19. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
    Economides MP; Rizzieri D; Pemmaraju N
    Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
    Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; GĆ¼tgemann I; Brossart P; Heine A
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.